Imatinib Levels and Genetic Factors in Cancer Treatment
Author Information
Author(s): Nicolas Widmer, L A Decosterd, S Leyvraz, M A Duchosal, A Rosselet, M Debiec-Rychter, C Csajka, J Biollaz, T Buclin
Primary Institution: Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
Hypothesis
How do imatinib-free plasma levels and target genotype affect the efficacy and tolerability of treatment in patients with chronic myeloid leukaemia and gastrointestinal stromal tumours?
Conclusion
Higher imatinib-free plasma levels are associated with better therapeutic responses and more side effects in patients with gastrointestinal stromal tumours.
Supporting Evidence
- Imatinib has improved treatment outcomes for chronic myeloid leukaemia and gastrointestinal stromal tumours.
- Free drug exposure correlated with the occurrence of side effects in patients.
- Patients with certain genetic mutations showed different responses to imatinib treatment.
Takeaway
This study shows that the amount of imatinib in the blood can help doctors decide how well the treatment will work and if it will cause side effects.
Methodology
The study used a nonlinear mixed effects population model to analyze pharmacokinetic parameters and their relationship with treatment response and side effects in 58 patients.
Potential Biases
Potential bias due to the observational nature of the study and the selection of patients based on their response to treatment.
Limitations
The study was observational and had a small sample size, which may limit the generalizability of the findings.
Participant Demographics
The study included 38 patients with gastrointestinal stromal tumours and 20 with chronic myeloid leukaemia, with a median age of 48 for GIST and 57 for CML.
Statistical Information
P-Value
P<0.001 for GIST response correlation
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website